Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|62|2|409-416

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.62, Iss.2, 2015-08, pp. : 409-416

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GSK2878175, a pan‐genotypic non‐nucleoside NS5B polymerase inhibitor, in healthy and treatment‐naïve chronic hepatitis C subjects

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 1, 2018-01 ,pp. : 19-27

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interleukin-11 for Treatment of Hepatitis C-Associated ITP

By  

Acta Haematologica, Vol. 119, Iss. 2, 2008-04 ,pp. : 126-132

Karger

Access to resources Recommend Favorite

JTK-853, a Novel Non-Nucleoside Hepatitis C Virus Polymerase Inhibitor, Demonstrates a High Genetic Barrier to Resistance in vitro

By  

Intervirology, Vol. 56, Iss. 5, 2013-07 ,pp. : 302-309

Karger

Access to resources Recommend Favorite

Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection

By  

Reviews on Recent Clinical Trials, Vol. 9, Iss. 2, 2014-06 ,pp. : 115-123

Bentham Science Publishers

Access to resources Recommend Favorite

Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 665-673

John Wiley & Sons Inc

Access to resources Recommend Favorite